Mind Cure has listed the warrants for trading from its recent financing. Warrants are valid until February 10, 2026, at an exercise price of CAD$0.80.
Mind Cure has listed the warrants for trading from its recent financing. Warrants are valid until February 10, 2026, at an exercise price of CAD$0.80.
A number of potential sector-wide catalysts for psychedelic stocks are already present or rapidly approaching.
Mind Cure closes on a CAD$23 million bought deal financing, after the full over-allotment was exercised.
After a torrid rally near the end of 2020, psychedelic drug stocks have been in a holding pattern. Here is why lift-off could occur at any time.
ATAI Life Sciences is set to become the new industry leader among psychedelic stocks. But it may not be the best OPPORTUNITY for investors when trading begins.
Mind Cure announces plans to roll out a line of pre- and post-treatment adaptogen supplements.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now